Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F21%3A10435862" target="_blank" >RIV/00216208:11140/21:10435862 - isvavai.cz</a>
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=3FmfYJFTQA" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=3FmfYJFTQA</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fonc.2021.757664" target="_blank" >10.3389/fonc.2021.757664</a>
Alternative languages
Result language
angličtina
Original language name
Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
Original language description
Transcription factor Growth Factor Independence 1 (GFI1) regulates the expression of genes important for survival, proliferation and differentiation of hematopoietic cells. A single nucleotide polymorphism (SNP) variant of GFI1 (GFI1-36N: serine replaced by asparagine at position 36), has a prevalence of 5-7% among healthy Caucasians and 10-15% in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) predisposing GFI-36N carriers to these diseases. Since GFI1 is implicated in B cell maturation and plasma cell (PC) development, we examined its prevalence in patients with multiple myeloma (MM), a haematological malignancy characterized by expansion of clonal PCs. Strikingly, as in MDS and AML, we found that the GFI1-36N had a higher prevalence among MM patients compared to the controls. In subgroup analyses, GFI1-36N correlates to a shorter overall survival of MM patients characterized by the presence of t(4;14) translocation and gain of 1q21 (<= 3 copies). MM patients carrying gain of 1q21 (>= 3 copies) demonstrated poor progression free survival. Furthermore, gene expression analysis implicated a role for GFI1-36N in epigenetic regulation and metabolism, potentially promoting the initiation and progression of MM.</p>
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
R - Projekt Ramcoveho programu EK
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Oncology [online]
ISSN
2234-943X
e-ISSN
—
Volume of the periodical
11
Issue of the periodical within the volume
October
Country of publishing house
CH - SWITZERLAND
Number of pages
8
Pages from-to
757664
UT code for WoS article
000717296000001
EID of the result in the Scopus database
2-s2.0-85118716093